Literature DB >> 15669587

Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin.

Patrik Andius1, Ole Damm, Sten Holmäng.   

Abstract

OBJECTIVE: To report prognostic factors and follow-up data for an unselected group of patients with carcinoma in situ (CIS) of the urinary bladder treated with bacille Calmette-Guérin (BCG).
MATERIAL AND METHODS: The clinical records of patients with CIS treated with BCG were reviewed. All 173 patients treated between 1986 and 1997 in four hospitals in two Swedish cities were included. The median follow-up period was 72 months (range 6-154 months). The impact of 18 variables on the times to recurrence and progression was studied using multivariate Cox proportional hazard regression and Kaplan-Meier analyses.
RESULTS: No pre-treatment variables, including type of CIS and T1G3 tumour, had prognostic value in terms of time to progression. The result of the first cystoscopy had a very strong prognostic importance: 44% of patients with a positive first cystoscopy progressed in stage, 59% were BCG failures and 35% died from urothelial cancer. The corresponding values for patients with a negative first cystoscopy were 11%, 18% and 8%. Fourteen patients (8%) were diagnosed with an upper urinary tract tumour but no variable had prognostic significance. The diagnoses of the upper urinary tract tumours were evenly distributed during follow-up.
CONCLUSIONS: We were not able to predict which patients would respond favourably to BCG. Cystectomy should be strongly considered even after a positive first cystoscopy. The accumulated incidence of patients with bladder CIS and a subsequent upper urinary tract tumour is rather high but it is questionable whether the prognosis will improve if routine follow-up urographies are performed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15669587     DOI: 10.1080/00365590410028692

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  4 in total

1.  Clinical outcome of primary versus secondary bladder carcinoma in situ.

Authors:  Daher C Chade; Shahrokh F Shariat; Ari Adamy; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-06-17       Impact factor: 7.450

2.  Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.

Authors:  Daher C Chade; Shahrokh F Shariat; Guilherme Godoy; Caroline J Savage; Angel M Cronin; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-07       Impact factor: 7.450

3.  Cyclin D3 gene amplification in bladder carcinoma in situ.

Authors:  Antonio Lopez-Beltran; Jose L Ordóñez; Ana P Otero; Ana Blanca; Vicky Sevillano; Marta Sanchez-Carbayo; Elisa Muñoz; Liang Cheng; Rodolfo Montironi; Enrique de Alava
Journal:  Virchows Arch       Date:  2010-09-07       Impact factor: 4.064

4.  Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter.

Authors:  Ho Kyung Seo; Jeong Bin Seo; Jae-Kook Nam; Kyung-Chae Jeong; Seung-Pil Shin; In-Hoo Kim; Sang Don Lee; Sang-Jin Lee
Journal:  Oncotarget       Date:  2014-07-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.